Publication:
Development of subfoveal nodule in Coats' disease: prevalence, stages, prognosis, and treatment

dc.contributor.coauthorYuksel, Murat
dc.contributor.coauthorOzdek, Sengul
dc.contributor.coauthorZeydanli, Ece Ozdemir
dc.contributor.coauthorAtalay, H. Tuba
dc.contributor.coauthorOzdemir, H. Baran
dc.contributor.coauthorGurelik, I. Gokhan
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorHasanreisoğlu, Murat
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-01-16T08:45:50Z
dc.date.available2026-01-16
dc.date.issued2025
dc.description.abstractPurpose: To investigate the prevalence, developmental stages, and factors affecting the progression of subfoveal nodules (SFN) in Coats' disease. Methods: A retrospective review of medical records and multimodal images was conducted for patients with Stage 2A-3A Coats' disease in a tertiary university setting. SFN development was classified into five stages: Stage 0 - macular exudation without subfoveal hard exudate; Stage 1 - subfoveal exudation; Stage 2 - consolidation of exudation; Stage 3- vascularization of SFN; Stage 4 - scarring and subfoveal fibrotic nodule. Factors influencing the formation and progression of SFN were analysed. Results: The study included 44 eyes of 43 patients, with a mean age of 6.9 +/- 4.1 years and a mean follow-up of 33 months. SFN prevalence was 48% initially and 91% at final follow-up. No differences were noted in baseline demographics or clinical characteristics across SFN stages. Patients developing SFN earlier than 9 months were significantly younger than those developing in a longer period (>9 months) (5.9 +/- 2.7 vs. 8.9 +/- 3.6, p = 0.037), and the mean number of intravitreal (IV) anti-VEGF/steroid injections applied per year was lower in the latter group (3.69 +/- 1.29 vs. 1.12 +/- 1.21, p = 0.001). The risk of early SFN development was 2.4 times higher in patients under 7 years and four times higher in those receiving three or fewer IV anti-VEGF/steroid injections per year. Conclusion: The prevalence of SFN (91%) in this study was found to be higher compared with the literature. More frequent anti-VEGF/steroid injections, compared with conventional treatment, may slow the progression of SFN.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1111/aos.70055
dc.identifier.eissn1755-3768
dc.identifier.embargoNo
dc.identifier.issn1755-375X
dc.identifier.pubmed41354905
dc.identifier.quartileQ1
dc.identifier.urihttps://doi.org/10.1111/aos.70055
dc.identifier.urihttps://hdl.handle.net/20.500.14288/32052
dc.identifier.wos001632530700001
dc.keywordsCoats' disease
dc.keywordsPrevalence of subfoveal nodule
dc.keywordsStaging of subfoveal nodule
dc.keywordsSubfoveal nodule
dc.language.isoeng
dc.publisherWiley
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofActa Ophthalmologica
dc.relation.openaccessNo
dc.rightsCopyrighted
dc.subjectOphthalmology
dc.titleDevelopment of subfoveal nodule in Coats' disease: prevalence, stages, prognosis, and treatment
dc.typeJournal Article
dspace.entity.typePublication
person.familyNameHasanreisoğlu
person.givenNameMurat
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files